{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:22:47Z","timestamp":1787678567857,"version":"build-2784847793"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC0864600"],"award-info":[{"award-number":["2021YFC0864600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","award":["DTQL-202401"],"award-info":[{"award-number":["DTQL-202401"]}],"id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110140","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:19:29Z","timestamp":1781885969000},"page":"110140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Azvudine (FNC), a next-generation cytidine analog with broad inhibitory activity against drug-resistant HIV-1 strains via stabilization of the reverse transcriptase catalytic complex"],"prefix":"10.1016","volume":"180","author":[{"given":"Xiaojie","family":"Lao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaozong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjie","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yantong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bioorg.2026.110140_bb0005","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2352-3018(24)00098-5","article-title":"Is HIV epidemic control by 2030 realistic?","volume":"11","author":"Beyrer","year":"2024","journal-title":"Lancet HIV"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110140_bb0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1473-3099(18)30647-9","article-title":"Global and regional molecular epidemiology of HIV-1, 1990\u20132015: a systematic review, global survey, and trend analysis","volume":"19","author":"Hemelaar","year":"2019","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110140_bb0015","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.idc.2019.05.004","article-title":"Management of virologic failure and HIV drug resistance","volume":"33","author":"McCluskey","year":"2019","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"10.1016\/j.bioorg.2026.110140_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.100238","article-title":"Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001\u20132017)","volume":"18","author":"Zuo","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bioorg.2026.110140_bb0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jclinepi.2022.02.005","article-title":"Acquired HIV drug resistance mutations on first-line antiretroviral therapy in southern Africa: systematic review and Bayesian evidence synthesis","volume":"148","author":"Hauser","year":"2022","journal-title":"J. Clin. Epidemiol."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110140_bb0030","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1093\/cid\/ciaa1161","article-title":"Pretreatment and acquired antiretroviral drug resistance among persons living with HIV in four African countries","volume":"73","author":"Crowell","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110140_bb0035","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/infdis\/jiae344","article-title":"Acquired human immunodeficiency virus type 1 drug resistance in Rhode Island, USA, 2004\u20132021","volume":"230","author":"Aung","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bioorg.2026.110140_bb0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coph.2019.03.003","article-title":"Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance","volume":"48","author":"Bandera","year":"2019","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110140_bb0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society-USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.bioorg.2026.110140_bb0050","series-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV","author":"Department of Health and Human Services (DHHS)","year":"2023"},{"key":"10.1016\/j.bioorg.2026.110140_bb0055","series-title":"Key Facts of HIV and AIDS","author":"World Health Organization","year":"2023"},{"key":"10.1016\/j.bioorg.2026.110140_bb0060","series-title":"Guidelines Version 12.0 October 2023","author":"European AIDS Clinical Society (EACS)","year":"2023"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110140_bb0065","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1128\/JVI.06597-11","article-title":"HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors","volume":"86","author":"Boyer","year":"2012","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110140_bb0070","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3390\/v2020372","article-title":"The role of nucleotide excision by reverse transcriptase in HIV drug resistance","volume":"2","author":"Acosta-Hoyos","year":"2010","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110140_bb0075","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","article-title":"Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments","volume":"98","author":"Men\u00e9ndez-Arias","year":"2013","journal-title":"Antivir. Res."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110140_bb0080","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1016\/j.ejmech.2011.06.020","article-title":"Synthesis of new 2\u2032-deoxy-2\u2032-fluoro-4\u2032-azido nucleoside analogues as potent anti-HIV agents","volume":"46","author":"Wang","year":"2011","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110140_bb0085","doi-asserted-by":"crossref","DOI":"10.1093\/narmme\/ugaf029","article-title":"Mechanism and spectrum of inhibition of viral polymerases by 2\u2032-deoxy-2\u2032-\u03b2-fluoro-4\u2032-azidocytidine or azvudine","volume":"2","author":"Lee","year":"2025","journal-title":"NAR Mol. Med."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110140_bb0090","article-title":"Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110140_bb0095","article-title":"Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110140_bb0100","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00204-20","article-title":"The pyrimidine Analog FNC potently inhibits the replication of multiple enteroviruses","volume":"94","author":"Xu","year":"2020","journal-title":"J. Virol."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110140_bb0105","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1021\/acs.jmedchem.0c00940","article-title":"Mechanistic insight into antiretroviral potency of 2\u2019-Deoxy-2\u2032-\u03b2-fluoro-4\u2032-azidocytidine (FNC) with a long-lasting effect on HIV-1 prevention","volume":"63","author":"Sun","year":"2020","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110140_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174112","article-title":"FNC efficiently inhibits mantle cell lymphoma growth","volume":"12","author":"Zhang","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110140_bb0115","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3892\/mmr.2013.1358","article-title":"The pyrimidine analog FNC inhibits cell proliferation and viral protein synthesis in HTLV-1-infected cells","volume":"7","author":"Wang","year":"2013","journal-title":"Mol. Med. Rep."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110140_bb0120","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3851\/IMP2292","article-title":"Novel nucleoside analogue FNC is effective against both wild-type and lamivudine-resistant HBV clinical isolates","volume":"17","author":"Zhou","year":"2012","journal-title":"Antivir. Ther."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110140_bb0125","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3851\/IMP2094","article-title":"Antiviral activity of FNC, 2\u2032-deoxy-2\u2032-\u03b2-fluoro-4\u2032-azidocytidine, against human and duck HBV replication","volume":"17","author":"Zheng","year":"2012","journal-title":"Antivir. Ther."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110140_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2551","article-title":"Azvudine versus Paxlovid in COVID-19: a systematic review and meta-analysis","volume":"34","author":"Amani","year":"2024","journal-title":"Rev. Med. Virol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110140_bb0135","first-page":"e24","article-title":"Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities","volume":"87","author":"Dian","year":"2023","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.bioorg.2026.110140_bb0140","article-title":"Advances in the effectiveness and safety of azvudine treatment: a comprehensive review","volume":"16","author":"Li","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110140_bb0145","article-title":"Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients","volume":"10","author":"de Souza","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110140_bb0150","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1128\/AAC.47.11.3377-3383.2003","article-title":"Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase","volume":"47","author":"Diallo","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2026.110140_bb0155","unstructured":"Stanford HIV Drug Resistance Database, NRTI Resistance Notes Version 10.2, 2025, Available from: https:\/\/hivdb.stanford.edu\/dr-summary\/resistance-notes\/NRTI\/. Accessed: 2026 May 5."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110140_bb0160","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/095632020701800603","article-title":"The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V","volume":"18","author":"Ly","year":"2007","journal-title":"Antivir. Chem. Chemother."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110140_bb0165","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1128\/AAC.48.4.1413-1415.2004","article-title":"Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine","volume":"48","author":"Stone","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110140_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067188","article-title":"Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in south African patients receiving first- and second-line antiretroviral treatment regimens","volume":"8","author":"Van Zyl","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110140_bb0175","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/135965350601100209","article-title":"The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations","volume":"11","author":"White","year":"2006","journal-title":"Antivir. Ther."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110140_bb0180","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1128\/jvi.70.11.8010-8018.1996","article-title":"An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3\u2032-azido-3\u2032-deoxythymidine","volume":"70","author":"Hooker","year":"1996","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110140_bb0185","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1073\/pnas.89.5.1934","article-title":"Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine","volume":"89","author":"Kellam","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110140_bb0190","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/00126334-200405010-00008","article-title":"Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens","volume":"36","author":"Kuritzkes","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110140_bb0195","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/jmv.10550","article-title":"Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure","volume":"72","author":"Marcelin","year":"2004","journal-title":"J. Med. Virol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110140_bb0200","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1128\/AAC.48.8.3122-3126.2004","article-title":"Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing","volume":"48","author":"Rhee","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110140_bb0205","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1177\/135965350501000705","article-title":"Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy","volume":"10","author":"Cozzi-Lepri","year":"2005","journal-title":"Antivir. Ther."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110140_bb0210","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/AAC.05487-11","article-title":"Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility","volume":"56","author":"Melikian","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2026.110140_bb0215","doi-asserted-by":"crossref","DOI":"10.1186\/1742-4690-8-31","article-title":"The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains","volume":"8","author":"Mbisa","year":"2011","journal-title":"Retrovirology"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110140_bb0220","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00224-17","article-title":"Structural insights into HIV reverse transcriptase mutations Q151M and Q151M complex that confer multinucleoside drug resistance","volume":"61","author":"Das","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2026.110140_bb0225","series-title":"2022 Update of the Drug Resistance Mutations in HIV-1","author":"IAS\u2013USA Drug Resistance Mutations Group","year":"2026"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110140_bb0230","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1128\/AAC.43.8.1961","article-title":"A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance","volume":"43","author":"Larder","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110140_bb0235","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2893.2010.01314.x","article-title":"Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors","volume":"18","author":"Mo","year":"2011","journal-title":"J. Viral Hepat."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110140_bb0240","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1089\/088922203769232629","article-title":"Protein binding in antiretroviral therapies","volume":"19","author":"Boffito","year":"2003","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110140_bb0245","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02038-21","article-title":"Forgiveness of INSTI-containing regimens at drug concentrations simulating variable adherence in vitro","volume":"66","author":"Acosta","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7742","key":"10.1016\/j.bioorg.2026.110140_bb0250","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","article-title":"A quantitative approach for measuring the reservoir of latent HIV-1 proviruses","volume":"566","author":"Bruner","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110140_bb0255","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1038\/s41598-020-59775-w","article-title":"Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine","volume":"10","author":"Yasutake","year":"2020","journal-title":"Sci. Rep."},{"issue":"33","key":"10.1016\/j.bioorg.2026.110140_bb0260","doi-asserted-by":"crossref","first-page":"9274","DOI":"10.1073\/pnas.1605223113","article-title":"Structural basis of HIV inhibition by translocation-defective RT inhibitor 4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine (EFdA)","volume":"113","author":"Salie","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110140_bb0265","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/ct100578z","article-title":"PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions","volume":"7","author":"Olsson","year":"2011","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.bioorg.2026.110140_bb0270","unstructured":"Schr\u00f6dinger. Available from: https:\/\/www.schrodinger.com\/products\/maestro. Accessed: 2023-01."},{"key":"10.1016\/j.bioorg.2026.110140_bb0275","unstructured":"Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters, Proceedings of the ACM\/IEEE Conference on Supercomputing(SC06), Tampa, Florida. Available from: http:\/\/sc06.supercomputing.org\/schedule\/event_detail.php?evid=9088. Accessed: 2023-01."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110140_bb0280","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1063\/1.463940","article-title":"Nos\u00e9\u2013Hoover chains: The canonical ensemble via continuous dynamics","volume":"97","author":"Martyna","year":"1992","journal-title":"J. Chem. Phys."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110140_bb0285","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1063\/1.467468","article-title":"Constant pressure molecular dynamics algorithms","volume":"101","author":"Martyna","year":"1994","journal-title":"J. Chem. Phys."},{"issue":"19","key":"10.1016\/j.bioorg.2026.110140_bb0290","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1063\/1.470117","article-title":"A smooth particle mesh Ewald method","volume":"103","author":"Essmann","year":"1995","journal-title":"J. Chem. Phys."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110140_bb0295","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1021\/acs.accounts.1c00697","article-title":"4\u2032-modified nucleosides for antiviral drug discovery: achievements and perspectives","volume":"55","author":"Chang","year":"2022","journal-title":"Acc. Chem. Res."},{"issue":"18","key":"10.1016\/j.bioorg.2026.110140_bb0300","doi-asserted-by":"crossref","first-page":"10027","DOI":"10.1073\/pnas.96.18.10027","article-title":"Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids","volume":"96","author":"Sarafianos","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"23","key":"10.1016\/j.bioorg.2026.110140_bb0305","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1093\/emboj\/cdf637","article-title":"Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA","volume":"21","author":"Sarafianos","year":"2002","journal-title":"EMBO J."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110140_bb0310","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/pro.3681","article-title":"Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase: first crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine","volume":"28","author":"Bertoletti","year":"2019","journal-title":"Protein Sci."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110140_bb0315","first-page":"411","article-title":"Nucleotide reverse transcriptase inhibitors: a thorough review, present status and future perspective as HIV therapeutics","volume":"15","author":"Holec","year":"2017","journal-title":"Curr. HIV Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110140_bb0320","doi-asserted-by":"crossref","first-page":"10553","DOI":"10.1038\/s41467-024-54618-y","article-title":"Structural basis of deoxynucleotide addition by HIV-1 RT during reverse transcription","volume":"15","author":"Vergara","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110140_bb0325","doi-asserted-by":"crossref","first-page":"547a","DOI":"10.1016\/j.bpj.2015.11.2927","article-title":"The effect of magnesium ion concentration on the nucleotide specificity and fidelity of HIV-1 reverse transcriptase","volume":"110","author":"Gong","year":"2016","journal-title":"Biophys. J."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110140_bb0330","doi-asserted-by":"crossref","first-page":"nwae331","DOI":"10.1093\/nsr\/nwae331","article-title":"2\u2019-fluorinated nucleoside chemistry for new drug discovery: achievements and prospects","volume":"11","author":"Meng","year":"2024","journal-title":"Natl. Sci. Rev."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110140_bb0335","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1021\/jm801595c","article-title":"The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4\u2032-azidocytidine against hepatitis C virus replication: the discovery of 4\u2032-azido-2\u2032-deoxy-2\u2032-fluorocytidine and 4\u2032-azido-2\u2032-dideoxy-2\u2032,2\u2032-difluorocytidine","volume":"52","author":"Smith","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110140_bb0340","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-4690-6-14","article-title":"Effects of the K65R and K65R\/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance","volume":"6","author":"Xu","year":"2009","journal-title":"Retrovirology"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110140_bb0345","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1073\/pnas.97.7.3056","article-title":"Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase","volume":"97","author":"Boyer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110140_bb0350","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1021\/acs.chemrev.0c00967","article-title":"Avoiding drug resistance in HIV reverse transcriptase","volume":"121","author":"Cilento","year":"2021","journal-title":"Chem. Rev."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110140_bb0355","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1021\/jm00086a013","article-title":"Synthesis and anti-HIV activity of 4\u2032-azido- and 4\u2032-methoxynucleosides","volume":"35","author":"Maag","year":"1992","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110140_bb0360","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02557-19","article-title":"Antiviral activity of tenofovir alafenamide against HIV-1 with thymidine analog-associated mutations and M184V","volume":"64","author":"Margot","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110140_bb0365","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jmb.2006.09.073","article-title":"Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine","volume":"365","author":"Cases-Gonz\u00e1lez","year":"2007","journal-title":"J. Mol. Biol."},{"issue":"Pt 11","key":"10.1016\/j.bioorg.2026.110140_bb0370","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1107\/S2053230X15017896","article-title":"Structure of the HIV-1 reverse transcriptase Q151M mutant: insights into the inhibitor resistance of HIV-1 reverse transcriptase and the structure of the nucleotide-binding pocket of hepatitis B virus polymerase","volume":"71","author":"Nakamura","year":"2015","journal-title":"Acta Crystallogr. Sect. F Struct. Biol. Commun."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110140_bb0375","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa2101609","article-title":"Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV","volume":"385","author":"Paton","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110140_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/v16091392","article-title":"Treatment management challenges in na\u00efve and experienced HIV-1-infected individuals carrying the M184V mutation","volume":"16","author":"Mimtsoudis","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.bioorg.2026.110140_bb0385","unstructured":"European AIDS Clinical Society (EACS), Guidelines Version 12.0 October, 2024, Available from: https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/. Accessed: 2025-3-12."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110140_bb0390","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.apsb.2024.03.032","article-title":"Selectively T cell phosphorylation activation of azvudine in the thymus tissue with immune protection effect","volume":"14","author":"Sheng","year":"2024","journal-title":"Acta Pharm. Sin. B"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826006760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826006760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:44:52Z","timestamp":1787676292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826006760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":78,"alternative-id":["S0045206826006760"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110140","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Azvudine (FNC), a next-generation cytidine analog with broad inhibitory activity against drug-resistant HIV-1 strains via stabilization of the reverse transcriptase catalytic complex","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110140"}}